Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients
Among hypertensive patients , cardiovascular disease morbidity is common , even in those who are adequately treated . New pharmacological strategies to mitigate the burden of arterial hypertension are needed . This 12-month , r and omized , double-blind placebo-controlled study investigated the effect of statin ( fluvastatin ) treatment on ambulatory blood pressure ( ABP ) , exercise blood pressure ( EBP ) , myocardial structure , endothelial function and insulin resistance in 50 hypertensive patients . At baseline , the groups were comparable in terms of demographic characteristics , ABP , EBP , endothelial function and homeostasis model assessment of insulin resistance ( HOMA-IR ) . At the end of the study , there was no difference between groups in terms of resting systolic blood pressure . However , maximum systolic EBP was lower in the treatment group than in the placebo group ( 175±18 vs 192±23 mm Hg , P<0.05 ) , as was left ventricular mass index ( LVMI ; 82±15 vs 100±23 , P<0.05 ) , and HOMA-IR index was lower after fluvastatin treatment ( 2.77±1.46 vs 3.33±1.73 , P<0.05 ) . Changes in lipid profile were not correlated with blood pressure , endothelial function , LVMI or HOMA-IR data . In hypertensive patients , fluvastatin can improve maximum systolic EBP , myocardial remodelling and insulin resistance , independently of lipid profile variations and endothelial function
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .